Guerbet (GBT), a global specialist in medical imaging, announces that the Ministry of Health & Welfare delivered registration for its innovative system for interventional oncology, Vectorio®, in Taiwan.
Vectorio® is a set of Lipiodol® Ultra Fluid resistant medical devices (1) including patented syringes, stopcock and sampling devices.
Vectorio® is dedicated for mixing and delivering Lipiodol® Ultra Fluid & anticancer drugs during cTACE procedure in adults with known, intermediate-stage hepatocellular carcinoma (HCC).
HCC is the most common primary liver cancer and is the fourth biggest cause of death due to cancer worldwide (2).
This medical device offers multiple advantages for healthcare professionals:
Designed and manufactured in France, Vectorio® 's commercial launch started in September 2017 in European countries. Today, Vectorio® is registered in 25 countries over the world: two countries where Vectorio® is registered for HCC imaging procedures, Canada & Germany; and 23 countries where Vectorio® is registered for cTACE procedures (3).
Guerbet's Vectorio, an Interventional Oncology Device, Receives Registration in Taiwan. Appl Radiol.